Recent Developments in Biotech News: In Vivo Gene Editing and Intellia Therapeutics

The hosts discuss the FDA clearance of Intellia Therapeutics' second in vivo CRISPR-based therapy for ATTRCM, exploring its potential impact and commercial prospects. They also delve into the promises and challenges of gene therapies and gene editing, including considerations of pricing and the need for long-term treatment.